A New Anti‐Immune Evasion Strategy against Methicillin‐Resistant Staphylococcus Aureus (MRSA) Infections: Simulating Complement Immunotherapy Based on Complement‐Mimic Antibiotic Delivery System
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Methicillin‐resistant Staphylococcus aureus (MRSA) can interfere with synergistic host defenses, thus escaping from immune surveillance. Herein, a new immunotherapy strategy‐simulating complement therapy is proposed. Two artificial effectors, Tat cell penetrating peptide and wheat germ agglutinin, are utilized to develop a multifunctional complement‐mimic liposome (CML) simultaneously delivering antibiotics and orchestrating the complement system with macrophages. The CML successfully simulates the functions of the complement system, including formation of a membrane attack complex, mediation of opsonophagocytosis, and activation of phagocytes. At infection sites, CMLs are able to recognize MRSA and disrupt bacterial permeation barriers (cell walls and cell membranes). Meanwhile, CMLs attached to the surface of MRSA are able to activate the phagocytosis and immune responses of macrophages. As a result, CMLs significantly increased the bacterial activity of clarithromycin both in vitro and in macrophages. Moreover, CMLs effectively reduced the MRSA burden in three infection models, including skin abscesses, pneumonia, and bacteremia mouse models. Therefore, the CML provides a novel strategy for overcoming bacterial immune evasion and sheds light on the development of immunotherapies for infectious diseases.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- A New Anti‐Immune Evasion Strategy against Methicillin‐Resistant <i>Staphylococcus Aureus</i> (MRSA) Infections: Simulating Complement Immunotherapy Based on Complement‐Mimic Antibiotic Delivery System
- Date Crossref
- 18/12/2020
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Chinese Academy of Medical Sciences & Peking Union Medical College pays non établi dans la noticeUniversité ou école supérieure
-
Peking University Beijing Key Laboratory of Molecular Pharmaceutics and New Drug System pays non établi dans la noticeUniversité ou école supérieure
-
Institute of Medicinal Biotechnology Chinese Academy of Medical Science and Peking Union Medical College Beijing 100050 China Institute of Medicinal Biotechnology pays non établi dans la noticeUniversité ou école supérieure
-
School of Pharmaceutical Sciences Beijing Key Laboratory of Molecular Pharmaceutics and New Drug System pays non établi dans la noticeUniversité ou école supérieure
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Molecular Pharmaceutics and New Drug System — Peking University et Institute of Medicinal Biotechnology — Institute of Medicinal Biotechnology Chinese Academy of Medical Science and Peking Union Medical College Beijing 100050 China, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.